These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization]. An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360 [TBL] [Abstract][Full Text] [Related]
6. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China. Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972 [TBL] [Abstract][Full Text] [Related]
7. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973 [TBL] [Abstract][Full Text] [Related]
8. Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma. Mincherton TI; Lam SJ; Clarke SE; Hui HYL; Malherbe JAJ; Chuah HS; Sidiqi MH; Fuller KA; Erber WN Int J Lab Hematol; 2024 Jun; 46(3):495-502. PubMed ID: 38379463 [TBL] [Abstract][Full Text] [Related]
10. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461 [TBL] [Abstract][Full Text] [Related]
11. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Smadbeck J; Peterson JF; Pearce KE; Pitel BA; Figueroa AL; Timm M; Jevremovic D; Shi M; Stewart AK; Braggio E; Riggs DL; Bergsagel PL; Vasmatzis G; Kearney HM; Hoppman NL; Ketterling RP; Kumar S; Rajkumar SV; Greipp PT; Baughn LB Blood Cancer J; 2019 Dec; 9(12):103. PubMed ID: 31844041 [TBL] [Abstract][Full Text] [Related]
12. [New concepts in multiple myeloma by returning to cytogenetics]. Tsukamoto T Rinsho Ketsueki; 2023; 64(5):411-417. PubMed ID: 37271533 [TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Sawyer JR Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186 [TBL] [Abstract][Full Text] [Related]
14. [Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma]. Gao L; Liu Q; Shi Y; Dang H; He Q; Wang Z; Feng L; Li Y; Wang XY; Li N; Song WJ; Wang YL; Kong S; Lu J; Huang XJ; Lai YY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):807-812. PubMed ID: 28641640 [TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases. Rack K; Vidrequin S; Dargent JL J Clin Pathol; 2016 Jan; 69(1):82-6. PubMed ID: 26338801 [TBL] [Abstract][Full Text] [Related]
16. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151 [TBL] [Abstract][Full Text] [Related]
17. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma]. Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084 [TBL] [Abstract][Full Text] [Related]
18. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB; Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249 [TBL] [Abstract][Full Text] [Related]
19. [Detection of Molecular Cytogenetic Aberrations by Fluorescence in Situ Hybridization in Different Bone Marrow Samples of Multiple Myeloma]. Wang YF; Wang H; Xi LY; Liu Y; Dong F; Wang JJ; Ke XY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1352-6. PubMed ID: 26524036 [TBL] [Abstract][Full Text] [Related]
20. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders. Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M; Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]